SK bioscience Advances Development of Next-Generation Infectious Disease Prevention Platform with Global Phase 1b CTA Submission for RSV Preventive Antibody Candidate

Summary

SK bioscience submitted a Phase 1b Clinical Trial Application (CTA) for RSM01, an RSV preventive antibody candidate, expanding its portfolio beyond vaccines into antibody-based preventive technologies. The Phase 1b study will evaluate safety and pharmacokinetics in approximately 80 infants aged 2 weeks to 8 months.